Abstract
Backgrounds: Targeted therapy is the foundation of personalized medicine in cancer, which is often understood as the right patient using the right drug. Thinking from the viewpoint of determinants during personalized drug treatment, the genetics, epigenetics and metagenomics would provide individual-specific biological elements to characterize the personalized responses for therapy.
Methods: Such personalized determinants should be not only understood as specific to one person, while they should have certain replicate observations in a group of individuals but not all, which actually provide more credible and reproducible personalized biological features. The requirement of detecting personalized determinants is well supported by novel high-throughput sequencing technologies and newly temporal-spatial experimental protocols, which quickly produce the omics big data.
Results: In this mini-review, we would like to give a brief introduction firstly on the advanced drug or drug-like therapy with genetics, epigenetics and metagenomics, respectively, from the viewpoint of personalized determinants; then summarize the computational methods helpful to analyze the corresponding omics data under the consideration of personalized biological context; and particularly focus on metagenomics to discuss current data, method, and opportunity for personalized medicine.
Conclusion: Totally, detecting personalized determinants during drug treatment from omics big data will bring the precision medicine or personalized medicine from concept to application. More and more inspiring biotechnologies, data resources, and analytic approaches will benefit All of US in the near future.
Keywords: Personalized determinants, drug treatment, omics, big data, biomarker, precision medicine.
Current Pharmaceutical Design
Title:Detecting Personalized Determinants During Drug Treatment from Omics Big Data
Volume: 24 Issue: 32
Author(s): Lu Wang, Xiangtian Yu, Chengming Zhang and Tao Zeng*
Affiliation:
- Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Chinese Academy Science, Shanghai 200031,China
Keywords: Personalized determinants, drug treatment, omics, big data, biomarker, precision medicine.
Abstract: Backgrounds: Targeted therapy is the foundation of personalized medicine in cancer, which is often understood as the right patient using the right drug. Thinking from the viewpoint of determinants during personalized drug treatment, the genetics, epigenetics and metagenomics would provide individual-specific biological elements to characterize the personalized responses for therapy.
Methods: Such personalized determinants should be not only understood as specific to one person, while they should have certain replicate observations in a group of individuals but not all, which actually provide more credible and reproducible personalized biological features. The requirement of detecting personalized determinants is well supported by novel high-throughput sequencing technologies and newly temporal-spatial experimental protocols, which quickly produce the omics big data.
Results: In this mini-review, we would like to give a brief introduction firstly on the advanced drug or drug-like therapy with genetics, epigenetics and metagenomics, respectively, from the viewpoint of personalized determinants; then summarize the computational methods helpful to analyze the corresponding omics data under the consideration of personalized biological context; and particularly focus on metagenomics to discuss current data, method, and opportunity for personalized medicine.
Conclusion: Totally, detecting personalized determinants during drug treatment from omics big data will bring the precision medicine or personalized medicine from concept to application. More and more inspiring biotechnologies, data resources, and analytic approaches will benefit All of US in the near future.
Export Options
About this article
Cite this article as:
Wang Lu, Yu Xiangtian , Zhang Chengming and Zeng Tao *, Detecting Personalized Determinants During Drug Treatment from Omics Big Data, Current Pharmaceutical Design 2018; 24 (32) . https://dx.doi.org/10.2174/1381612824666181106102111
DOI https://dx.doi.org/10.2174/1381612824666181106102111 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Marine Bromopyrrole Alkaloids: Synthesis and Diverse Medicinal Applications
Current Topics in Medicinal Chemistry Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Alcohol Abuse and Pancreatic Diseases: An Overview
Recent Patents on Inflammation & Allergy Drug Discovery <i>In-vitro</i> Comparative Study of Different Brands of Metoclopramide Hydrochloride Tablets Marketed in Saudi Arabia
Current Drug Therapy Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design ent-Kaurane Diterpenoids from Croton tonkinensis Induce Apoptosis in Colorectal Cancer Cells through the Phosphorylation of JNK Mediated by Reactive Oxygen Species and Dual-Specificity JNK Kinase MKK4
Anti-Cancer Agents in Medicinal Chemistry Human Mesotrypsin Defies Natural Trypsin Inhibitors: From Passive Resistance to Active Destruction.
Protein & Peptide Letters The Effect of Proton Pump Inhibitors on the Human Microbiota
Current Drug Metabolism The Competence of 7,8-Diacetoxy-4-Methylcoumarin and Other Polyphenolic Acetates in Mitigating the Oxidative Stress and their Role in Angiogenesis
Current Topics in Medicinal Chemistry 3-Substituted Isocoumarins as Thymidine Phosphorylase Inhibitors
Letters in Drug Design & Discovery Glutathione Transferases: Emerging Multidisciplinary Tools in Red and Green Biotechnology
Recent Patents on Biotechnology Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue Presenting as Multiple Pulmonary Lesions: Case Report and Review of the Literature
Current Respiratory Medicine Reviews Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Editorial (Thematic Issue: Nanotechnology for Drug Delivery: Part II)
Current Pharmaceutical Design Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry